Adding fostemsavir to reduce inflammation in people with well-controlled HIV

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, open-label Phase 2b trial comparing the addition of fostemsavir (600 mg daily) to participants' existing antiretroviral therapy versus continuing standard care alone over 24 months. Eligible participants are people living with HIV who have undetectable plasma viral load, detectable soluble gp120 (sgp120), and at least one cardiovascular risk factor. Outcomes include imaging measures (such as perivascular fat attenuation index and uncalcified plaque volume), blood biomarkers of inflammation and immune activation, and clinical cardiovascular endpoints. The trial is led by Centre hospitalier de l'Université de Montréal (CR CHUM) with academic collaborators and will enroll participants at the Montreal site.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 40 years or older, or have lived with HIV for 25 years or more, any sex;
* Undetectable HIV viral load (defined as last viral load measurement less than 50 copies/ml within the last 6 months);
* Presence of at least one cardiovascular risk factor among the following: longstanding HIV infection (25 years or more), hypertension, diabetes, past or present smoking, dyslipidemia, family history of early onset CVD in a first-degree relative (defined as younger than 55 in males or younger than 65 in females (80)), known previous cardiovascular disease (defined as past myocardial infarction, coronary revascularization, stroke, or coronary artery atherosclerosis with \>= 50% stenosis demonstrated on coronary angiography or CCTA);
* Participants with past cardiovascular disease must be in a stable clinical condition as judged by the study clinicians;
* Past cardiovascular events are defined as having occurred at least 3 months before screening;
* Evidence of detectable plasmatic sgp120 levels at any point in the past year, using the assay described priorly and performed at CRCHUM in Dr Andrés Finzi's laboratory.

Exclusion Criteria:

* Known allergy to study drug;
* Concomitant treatment with strong cytochrome P450 (CYP3A) inducers, including but not limited to: carbamazepine, phenytoin (anticonvulsants), mitotane (antineoplastic), enzalutamide (androgen receptor inhibitor), rifampicin (antimycobacterial) and St John's wort (Hypericum perforatum, herbal supplement);
* Planning to become pregnant, pregnant, or breastfeeding (as requested per product monography (55)). Females of childbearing potential must have a negative pregnancy test at baseline visit, and follow contraception requirements throughout the treatment;
* Contraindication for CT scan use (estimated glomerular filtration rate \[eGFR\] less than 40ml/min using the Modification of Diet in Renal Diseases \[MDRD\] formula or iodine allergy);
* Elevated risk of prior ionizing radiation exposure outside clinical care exceeding 10 mSV over 3 years, per the investigator's judgement (eg. a participant with occupational ionizing radiation exposure, prior participation in clinical trials with multiple CT scans)
* Confirmed uncorrected QT value \>500ms or confirmed QTcF \>470 msec for women and \>450 msec for men;
* Acquired/ congenital long QT syndrome;
* Current or anticipated treatment with any of the following medications: amiodarone, disopyramide, dofetilide, ibutilide, procainamide, sotalol, and quinidine;
* Unstable liver disease (as defined by any of the following: presence of ascites, encephalopathy, coagulopathy (INR \> 2.0), hypoalbuminemia (\<30 mg/ml), untreated esophageal or gastric varices, or persistently elevated bilirubinemia (\>1.5x upper limit of normal \[ULN\]), known biliary abnormalities (except Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment);
* ALT \>=5 times the ULN, OR ALT \>=3xULN and bilirubin \>=1.5xULN with \>35% direct bilirubin;
* History of liver cirrhosis with CHILD-PUGH classification C;
* Inability to provide informed consent;
* Life expectancy of less than 36 months;
* Inability to present to study visits;
* Participation in another interventional trial;
* Known Congestive heart failure with NYHA class 3 or 4.

Where it's running

• Cr Chum
  Montreal, Quebec, Canada Recruiting

Study contacts

• Principal investigator: Madeleine Durand, MD MSc FRCPC — Cr Chum
• Study coordinator: Branka Vulesevic, TRIAL MANAGER
• Email: branka.vulesevic.chum@ssss.gouv.qc.ca
• Phone: 15148908000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cervical screening and care options for women living with HIV who test positive for high-risk HPV

  This study tests different ways to screen and manage high-risk HPV in women with HIV to see what might work best for them.

  Recruiting University of California, San Diego · Nairobi · NCT07925307

• See if stopping alcohol can lower blood pressure and heart risk in adults who drink and have hypertension

  This study tests whether abstaining from alcohol for 8 weeks can improve blood pressure and heart-health markers in adults who regularly drink and have high blood pressure.

  Recruiting The University of Texas at Arlington · Arlington, Texas · NCT07783061

• Psilocybin Therapy for MeUD and HIV

  This study tests whether a single psilocybin dose, paired with motivational support therapy, can help people with HIV and moderate-to-severe methamphetamine use disorder stop using methamphetamine.

  Recruiting Phase 2 University of California, San Francisco · San Francisco, California · NCT07756736

• Voluntary HIV screening among adults in France

  This study will see which voluntary HIV testing methods adults in France use.

  Recruiting Université de Reims Champagne-Ardenne · Reims · NCT07418385

• PrEP delivery led by HIV testing counselors in Kenyan clinics

  A counselor-led approach is being tested to see if it helps deliver PrEP in public health clinics for people in Kenya who may be at risk for HIV.

  Recruiting University of Washington · Kisumu · NCT07089966

• Monthly MK-8527 to prevent HIV-1 infection

  This study will test whether taking MK-8527 once a month prevents HIV-1 better than daily oral PrEP in HIV-negative, sexually active cisgender women.

  Recruiting at 21 sites Phase 3 Merck Sharp & Dohme LLC · Homabay County, Homa Bay County and 29 other locations · NCT07071623

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.